Instil Bio, Inc. (TIL) NASDAQ

9.16

-0.34(-3.58%)

Updated at February 20 04:00PM

Currency In USD

Instil Bio, Inc.

Address

3963 Maple Avenue

Dallas, TX 75219

United States of America

Phone

972 499 3350

Sector

Healthcare

Industry

Biotechnology

Employees

14

First IPO Date

March 19, 2021

Key Executives

NameTitlePayYear Born
Bronson CrouchChairman & Chief Executive Officer1.65M1973
Sandeep LaumasChief Financial Officer & Chief Business Officer1.02M1969
James FreedmanChief Medical Officer0N/A
Qiying LuChief Medical Officer & Senior Vice President of China01975
Rupal BhattSenior Vice President of Science & Translational Medicine0N/A

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.